Fewer patients will be receiving the erythropoiesis-stimulating agents (ESAs) Procrit, Epogen, and Aranesp
June 2007
Fewer patients will be receiving the erythropoiesis-stimulating agents (ESAs) Procrit, Epogen, and Aranesp.
Chronic kidney disease. ESAs are associated with an increase in death and cardiovascular events when used to boost hemoglobin above 12 g/dL. These drugs can increase thrombosis risk.
Kidney guidelines will recommend aiming for lower hemoglobin targets in the range of 11 to 12 g/dL.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote